Inhibition of the Cardiac Fibroblast–Enriched lncRNA Meg3 Prevents Cardiac Fibrosis and Diastolic Dysfunction
- 18 August 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 121 (5), 575-583
- https://doi.org/10.1161/circresaha.117.310624
Abstract
Rationale: Cardiac fibroblasts (CFs) drive extracellular matrix remodeling after pressure overload, leading to fibrosis and diastolic dysfunction. Recent studies described the role of long noncoding RNAs (lncRNAs) in cardiac pathologies. Nevertheless, detailed reports on lncRNAs regulating CF biology and describing their implication in cardiac remodeling are still missing. Objective: Here, we aimed at characterizing lncRNA expression in murine CFs after chronic pressure overload to identify CF-enriched lncRNAs and investigate their function and contribution to cardiac fibrosis and diastolic dysfunction. Methods and Results: Global lncRNA profiling identified several dysregulated transcripts. Among them, the lncRNA maternally expressed gene 3 (Meg3) was found to be mostly expressed by CFs and to undergo transcriptional downregulation during late cardiac remodeling. In vitro, Meg3 regulated the production of matrix metalloproteinase-2 (MMP-2). GapmeR-mediated silencing of Meg3 in CFs resulted in the downregulation of Mmp-2 transcription, which, in turn, was dependent on P53 activity both in the absence and in the presence of transforming growth factor-β I. Chromatin immunoprecipitation showed that further induction of Mmp-2 expression by transforming growth factor-β I was blocked by Meg3 silencing through the inhibition of P53 binding on the Mmp-2 promoter. Consistently, inhibition of Meg3 in vivo after transverse aortic constriction prevented cardiac MMP-2 induction, leading to decreased cardiac fibrosis and improved diastolic performance. Conclusions: Collectively, our findings uncover a critical role for Meg3 in the regulation of MMP-2 production by CFs in vitro and in vivo, identifying a new player in the development of cardiac fibrosis and potential new target for the prevention of cardiac remodeling.Keywords
This publication has 25 references indexed in Scilit:
- MEG3 noncoding RNA: a tumor suppressorJournal of Molecular Endocrinology, 2012
- Increased Expression of Angiogenic Genes in the Brains of Mouse Meg3-Null EmbryosEndocrinology, 2010
- MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure*Archives of Physiology and Biochemistry, 2010
- Maternally Expressed Gene 3 (MEG3) Noncoding Ribonucleic Acid: Isoform Structure, Expression, and FunctionsEndocrinology, 2009
- Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and FunctionPhysiological Reviews, 2007
- Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure OverloadHypertension, 2006
- Hypermethylation of the Promoter Region Is Associated with the Loss ofMEG3Gene Expression in Human Pituitary TumorsJournal of Clinical Endocrinology & Metabolism, 2005
- A Theoretical Model of Type I Collagen Proteolysis by Matrix Metalloproteinase (MMP) 2 and Membrane Type 1 MMP in the Presence of Tissue Inhibitor of Metalloproteinase 2Online Journal of Public Health Informatics, 2004
- Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy.Proceedings of the National Academy of Sciences of the United States of America, 1991